세계의 진행성 신세포암(RCC) 치료 시장 보고서(2025년)

Advanced Renal Cell Carcinoma Treatment Global Market Report 2025

US $ 4,490 ￦ 6,342,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,167,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,992,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

진행성 신세포암(RCC) 치료 시장 규모는 향후 수년간 강력한 성장이 전망될 예정입니다. 주요 동향에는 진단 기술의 발전, 표적 치료의 혁신, 경구 치료 옵션의 개발, 액체 생검 기술의 발전, 신약 개발에 인공지능의 통합 등이 있습니다.

유전적 질환의 유병률 증가는 진행성 신세포암(RCC) 치료 시장의 성장을 가속할 것으로 예측됩니다. 또한 유전성 질환의 이환율 증가는 진단기술의 진보, 인지도의 향상과 보고, 유전적 소인과 상호작용하는 환경이나 라이프스타일의 요인에 기인하고 있습니다. 유전 질환의 발병률 증가는 진단 기술의 발전, 인식 및 보고의 향상, 유전적 소인과 상호작용하는 환경 및 생활 습관 요인에 기인합니다. 진행성 신세포암종(RCC) 치료는 특정 분자 경로를 표적으로 하여 종양 발생 및 진행의 유전적 요인을 해결하는 개인 맞춤형 치료를 가능하게 함으로써 유전적 상태를 관리하는 데 중요한 역할을 합니다. 예를 들어, 2023년 6월 영국에 등록된 자선단체인 Gene People은 어린이 25명 중 1명이 유전 질환의 영향을 받고 있으며, 영국에서 240만 명 이상이 유전 질환을 앓고 있는 것으로 추정했습니다. 또한 영국에서는 매년 약 3만 명의 신생아와 어린이가 유전 질환 진단을 받습니다. 그 결과, 유전성 질환의 유병률 증가가 진행성 신세포암(RCC) 치료 시장의 확대에 박차를 가하고 있습니다.

진행성 신세포암(RCC) 치료 시장의 주요 기업은 치료효과와 환자의 결과를 개선하기 위해 저산소 유도인자-2α(HIF-2a) 억제제 등의 혁신적인 치료법의 개발에 주력하고 있습니다. 이 약은 저산소증 수준에 대한 신체 반응을 조절하는 단백질 인 HIF-2a의 활성을 억제하도록 설계된 약물 클래스별입니다. 예를 들어, 2023년 12월, 미국에 본사를 둔 헬스케어 기업 Merck & Co. 는 경구용 HIF-2a 억제제인 웰리레그(벨주티판)에 대한 미국 식품의약국(FDA)의 승인을 받았습니다. 전 치료력이 있는 환자를 대상으로 하고 있습니다. 이번 승인은 치료 옵션이 한정되어 있는 환자 집단에 새로운 치료 옵션을 도입하는 것으로, 진행 RCC의 질환 관리와 결과를 개선할 가능성을 제공하는 것이기 때문에 의미 있는 것입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 진행성 신세포암(RCC) 치료 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인과 억제요인)
• 최종 이용 산업의 분석
• 세계의 진행성 신세포암(RCC) 치료 시장 : 성장률 분석
• 세계의 진행성 신세포암(RCC) 치료 시장 실적 : 규모와 성장(2019-2024년)
• 세계의 진행성 신세포암(RCC) 치료 시장 예측 : 규모와 성장(2024-2029년, 2034년)
• 세계의 진행성 신세포암(RCC) 치료 전체 시장(TAM)

제6장 시장 세분화

• 세계의 진행성 신세포암(RCC) 치료 시장 : 치료별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 생물학적 제제
• 방사선 치료
• 화학 치료
• 호르몬
• 백신 치료
• 기타 치료
• 세계의 진행성 신세포암(RCC) 치료 시장 : 투여 경로별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 부모
• 경구
• 기타 투여 경로
• 세계의 진행성 신세포암(RCC) 치료 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 병원
• 암 연구기관
• 외래수술센터(ASC)
• 기타 최종 사용자
• 세계의 진행성 신세포암(RCC) 치료 시장 : 생물학적 제제 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 단클론 항체
• 면역 체크포인트 억제제
• 사이토카인 요법
• 표적 저분자 억제제
• 세계의 진행성 신세포암(RCC) 치료 시장 : 방사선 치료 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 외부 빔 방사선 치료(EBRT)
• 정위적 체부 방사선 치료(SBRT)
• 양성자 빔 치료
• 세계의 진행성 신세포암(RCC) 치료 시장 : 화학 치료 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 백금 기반 화학 치료
• 항대사제
• 알킬화제
• 세계의 진행성 신세포암(RCC) 치료 시장 : 호르몬 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 안드로겐 결핍 요법(ADT)
• 에스트로겐 수용체 조절제
• 세계의 진행성 신세포암(RCC) 치료 시장 : 백신 치료 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 펩타이드 기반 암 백신
• 수지상 세포 백신
• DNA 기반 암 백신
• 세계의 진행성 신세포암(RCC) 치료 시장 : 기타 치료 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 냉동 절제술
• 고주파 절제술(RFA)
• 병용 요법

제7장 지역별/국가별 분석

• 세계의 진행성 신세포암(RCC) 치료 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 진행성 신세포암(RCC) 치료 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

• 진행성 신세포암(RCC) 치료 시장 : 경쟁 구도
• 진행성 신세포암(RCC) 치료 시장 : 기업 프로파일
  • Pfizer Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • Merck & Co. Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • AbbVie Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • Bristol-Myers Squibb Company 개요, 제품 및 서비스, 전략 및 재무 분석
  • AstraZeneca PLC 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

• Novartis International AG
• Takeda Pharmaceutical Company Limited
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Ipsen SA
• Exelixis Inc.
• BeiGene Ltd.
• Bavarian Nordic A/S
• Telix Pharmaceuticals Limited
• CRISPR Therapeutics AG
• Beijing Scitech-Mq Pharmaceuticals Limited
• HUTCHMED(China)Limited
• Arcus Biosciences Inc.
• NGM Biopharmaceuticals Inc.
• Mirati Therapeutics Inc.

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

• 진행성 신세포암(RCC) 치료 시장(2029년) : 새로운 기회를 제공하는 국가
• 진행성 신세포암(RCC) 치료 시장(2029년) : 새로운 기회를 제공하는 부문
• 진행성 신세포암(RCC) 치료 시장(2029년) : 성장 전략
  • 시장 동향에 기초한 전략
  • 경쟁 전략

제36장 부록

KTH

영문 목차

영문목차

Advanced renal cell carcinoma (RCC) treatment encompasses medical interventions and therapies designed to manage and improve outcomes in later stages of the disease, where the cancer has spread beyond the kidney. These treatments typically include targeted therapies, immunotherapy, and, in some cases, radiation therapy to slow cancer progression and relieve symptoms.

The primary treatment options for advanced renal cell carcinoma (RCC) consist of biologics, radiation therapy, chemotherapy, hormone therapy, vaccine therapy, and other approaches. Biologics, which are derived from living organisms, specifically target cancer cells and boost the immune system, playing a crucial role in advanced RCC treatment. These medications can be administered via different routes, including parenteral, oral, and others. Various healthcare providers, such as hospitals, cancer research institutes, ambulatory surgical centers, and others, utilize these treatments.

The advanced renal cell carcinoma (RCC) treatment market research report is one of a series of new reports from The Business Research Company that provides advanced renal cell carcinoma (RCC) treatment market statistics, including the advanced renal cell carcinoma (RCC) treatment industry global market size, regional shares, competitors with the advanced renal cell carcinoma (RCC) treatment market share, detailed advanced renal cell carcinoma (RCC) treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the advanced renal cell carcinoma (RCC) treatment industry. This advanced renal cell carcinoma (RCC) treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The advanced renal cell carcinoma treatment market size has grown strongly in recent years. It will grow from $8.10 billion in 2024 to $8.75 billion in 2025 at a compound annual growth rate (CAGR) of 8.1%. The growth during the historic period can be attributed to the rising geriatric population, an increasing prevalence of smoking, a surge in hypertension cases, higher healthcare expenditure, and a growing number of renal cancer cases.

The advanced renal cell carcinoma treatment market size is expected to see strong growth in the next few years. It will grow to $11.77 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be driven by the increasing incidence of genetic conditions, the rising prevalence of chronic high blood pressure, the adoption of tyrosine kinase inhibitors, greater awareness of kidney cancer, and increased investments in research and development. Key trends include technological advancements in diagnostics, innovations in targeted therapies, the development of oral treatment options, progress in liquid biopsy technology, and the integration of artificial intelligence in drug development.

The increasing prevalence of genetic conditions is expected to drive the growth of the advanced renal cell carcinoma (RCC) treatment market. Genetic conditions are disorders or diseases resulting from DNA abnormalities, which may be inherited from parents or arise due to mutations occurring during an individual's lifetime. The rising incidence of genetic conditions is attributed to advancements in diagnostic technologies, improved awareness and reporting, as well as environmental and lifestyle factors that interact with genetic predispositions. Advanced renal cell carcinoma (RCC) treatment plays a crucial role in managing genetic conditions by targeting specific molecular pathways, enabling personalized therapies that address the genetic drivers of tumor development and progression. For example, in June 2023, Gene People, a UK-based registered charity, estimated that 1 in 25 children is affected by genetic conditions, with more than 2.4 million individuals in the UK living with a genetic disorder. Additionally, approximately 30,000 newborns and children are diagnosed with genetic conditions annually in the UK. As a result, the increasing prevalence of genetic conditions is fueling the expansion of the advanced renal cell carcinoma (RCC) treatment market.

Leading companies in the advanced renal cell carcinoma (RCC) treatment market are focusing on the development of innovative therapies, such as hypoxia-inducible factor-2 alpha (HIF-2a) inhibitors, to improve treatment effectiveness and patient outcomes. HIF-2a inhibitors are a class of drugs designed to block the activity of HIF-2a, a protein that regulates the body's response to low oxygen levels. For instance, in December 2023, Merck & Co. Inc., a US-based healthcare company, received U.S. Food and Drug Administration (FDA) approval for WELIREG (belzutifan), an oral HIF-2a inhibitor. This groundbreaking treatment is specifically intended for patients previously treated with PD-1 or PD-L1 inhibitors and VEGF-TKI therapies. The approval is significant as it introduces a novel therapeutic option for a patient population with limited treatment alternatives, offering potential for improved disease management and outcomes in advanced RCC.

In December 2023, Exelixis Inc., a US-based biotechnology company, entered into a partnership with Arcus Biosciences Inc. to accelerate the development of novel cancer therapies. Through this collaboration, Exelixis and Arcus Biosciences aim to advance treatments for advanced renal cell carcinoma and other solid tumors, leveraging the STELLAR-009 clinical trial to drive innovation. Arcus Biosciences Inc. is a US-based biotechnology company specializing in renal cell carcinoma treatment solutions.

Major players in the advanced renal cell carcinoma treatment market are Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Takeda Pharmaceutical Company Limited, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Ipsen SA, Exelixis Inc., BeiGene Ltd., Bavarian Nordic A/S, Telix Pharmaceuticals Limited, CRISPR Therapeutics AG, Beijing Scitech-Mq Pharmaceuticals Limited, HUTCHMED (China) Limited, Arcus Biosciences Inc., NGM Biopharmaceuticals Inc., Mirati Therapeutics Inc.

North America was the largest region in the advanced renal cell carcinoma treatment market in 2024. The regions covered in advanced renal cell carcinoma treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the advanced renal cell carcinoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The advanced renal cell carcinoma (RCC) treatment market includes revenues earned by entities by providing services such as targeted therapy administration, nephrectomy, medical consultation services, and supportive care services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Advanced Renal Cell Carcinoma Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on advanced renal cell carcinoma treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for advanced renal cell carcinoma treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The advanced renal cell carcinoma treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Biologics; Radiation Therapy; Chemotherapy; Hormone; Vaccine Therapy; Other Treatments
• 2) By Route Of Administration: Parental; Oral; Other Route Of Administrations
• 3) By End User: Hospitals; Cancer Research Institutes; Ambulatory Surgical Centers; Other End Users
• Subsegments:
• 1) By Biologics: Monoclonal Antibodies; Immune Checkpoint Inhibitors; Cytokine Therapy; Targeted Small Molecule Inhibitors
• 2) By Radiation Therapy: External Beam Radiation Therapy (EBRT); Stereotactic Body Radiation Therapy (SBRT); Proton Beam Therapy
• 3) By Chemotherapy: Platinum-Based Chemotherapy; Antimetabolites; Alkylating Agents
• 4) By Hormone Therapy: Androgen Deprivation Therapy (ADT); Estrogen Receptor Modulators
• 5) By Vaccine Therapy: Peptide-Based Cancer Vaccines; Dendritic Cell Vaccines; DNA-Based Cancer Vaccines
• 6) By Other Treatments: Cryoablation; Radiofrequency Ablation (RFA); Combination Therapy
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; AbbVie Inc.; Bristol-Myers Squibb Company; AstraZeneca PLC
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Advanced Renal Cell Carcinoma Treatment Market Characteristics

3. Advanced Renal Cell Carcinoma Treatment Market Trends And Strategies

4. Advanced Renal Cell Carcinoma Treatment Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Advanced Renal Cell Carcinoma Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Advanced Renal Cell Carcinoma Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Advanced Renal Cell Carcinoma Treatment Market Growth Rate Analysis
• 5.4. Global Advanced Renal Cell Carcinoma Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Advanced Renal Cell Carcinoma Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Advanced Renal Cell Carcinoma Treatment Total Addressable Market (TAM)

6. Advanced Renal Cell Carcinoma Treatment Market Segmentation

• 6.1. Global Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Biologics
• Radiation Therapy
• Chemotherapy
• Hormone
• Vacccine Therapy
• Other Treatments
• 6.2. Global Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Parental
• Oral
• Other Route Of Administrations
• 6.3. Global Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Cancer Research Institutes
• Ambulatory Surgical Centers
• Other End Users
• 6.4. Global Advanced Renal Cell Carcinoma Treatment Market, Sub-Segmentation Of Biologics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Immune Checkpoint Inhibitors
• Cytokine Therapy
• Targeted Small Molecule Inhibitors
• 6.5. Global Advanced Renal Cell Carcinoma Treatment Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• External Beam Radiation Therapy (EBRT)
• Stereotactic Body Radiation Therapy (SBRT)
• Proton Beam Therapy
• 6.6. Global Advanced Renal Cell Carcinoma Treatment Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Platinum-Based Chemotherapy
• Antimetabolites
• Alkylating Agents
• 6.7. Global Advanced Renal Cell Carcinoma Treatment Market, Sub-Segmentation Of Hormone Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Androgen Deprivation Therapy (ADT)
• Estrogen Receptor Modulators
• 6.8. Global Advanced Renal Cell Carcinoma Treatment Market, Sub-Segmentation Of Vaccine Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Peptide-Based Cancer Vaccines
• Dendritic Cell Vaccines
• DNA-Based Cancer Vaccines
• 6.9. Global Advanced Renal Cell Carcinoma Treatment Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cryoablation
• Radiofrequency Ablation (RFA)
• Combination Therapy

7. Advanced Renal Cell Carcinoma Treatment Market Regional And Country Analysis

• 7.1. Global Advanced Renal Cell Carcinoma Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Advanced Renal Cell Carcinoma Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Advanced Renal Cell Carcinoma Treatment Market

• 8.1. Asia-Pacific Advanced Renal Cell Carcinoma Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Advanced Renal Cell Carcinoma Treatment Market

• 9.1. China Advanced Renal Cell Carcinoma Treatment Market Overview
• 9.2. China Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Advanced Renal Cell Carcinoma Treatment Market

• 10.1. India Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Advanced Renal Cell Carcinoma Treatment Market

• 11.1. Japan Advanced Renal Cell Carcinoma Treatment Market Overview
• 11.2. Japan Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Advanced Renal Cell Carcinoma Treatment Market

• 12.1. Australia Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Advanced Renal Cell Carcinoma Treatment Market

• 13.1. Indonesia Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Advanced Renal Cell Carcinoma Treatment Market

• 14.1. South Korea Advanced Renal Cell Carcinoma Treatment Market Overview
• 14.2. South Korea Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Advanced Renal Cell Carcinoma Treatment Market

• 15.1. Western Europe Advanced Renal Cell Carcinoma Treatment Market Overview
• 15.2. Western Europe Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Advanced Renal Cell Carcinoma Treatment Market

• 16.1. UK Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Advanced Renal Cell Carcinoma Treatment Market

• 17.1. Germany Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Advanced Renal Cell Carcinoma Treatment Market

• 18.1. France Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Advanced Renal Cell Carcinoma Treatment Market

• 19.1. Italy Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Advanced Renal Cell Carcinoma Treatment Market

• 20.1. Spain Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Advanced Renal Cell Carcinoma Treatment Market

• 21.1. Eastern Europe Advanced Renal Cell Carcinoma Treatment Market Overview
• 21.2. Eastern Europe Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Advanced Renal Cell Carcinoma Treatment Market

• 22.1. Russia Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Advanced Renal Cell Carcinoma Treatment Market

• 23.1. North America Advanced Renal Cell Carcinoma Treatment Market Overview
• 23.2. North America Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Advanced Renal Cell Carcinoma Treatment Market

• 24.1. USA Advanced Renal Cell Carcinoma Treatment Market Overview
• 24.2. USA Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Advanced Renal Cell Carcinoma Treatment Market

• 25.1. Canada Advanced Renal Cell Carcinoma Treatment Market Overview
• 25.2. Canada Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Advanced Renal Cell Carcinoma Treatment Market

• 26.1. South America Advanced Renal Cell Carcinoma Treatment Market Overview
• 26.2. South America Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Advanced Renal Cell Carcinoma Treatment Market

• 27.1. Brazil Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Advanced Renal Cell Carcinoma Treatment Market

• 28.1. Middle East Advanced Renal Cell Carcinoma Treatment Market Overview
• 28.2. Middle East Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Advanced Renal Cell Carcinoma Treatment Market

• 29.1. Africa Advanced Renal Cell Carcinoma Treatment Market Overview
• 29.2. Africa Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Advanced Renal Cell Carcinoma Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Advanced Renal Cell Carcinoma Treatment Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Advanced Renal Cell Carcinoma Treatment Market Competitive Landscape And Company Profiles

• 30.1. Advanced Renal Cell Carcinoma Treatment Market Competitive Landscape
• 30.2. Advanced Renal Cell Carcinoma Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

31. Advanced Renal Cell Carcinoma Treatment Market Other Major And Innovative Companies

• 31.1. Novartis International AG
• 31.2. Takeda Pharmaceutical Company Limited
• 31.3. Regeneron Pharmaceuticals Inc.
• 31.4. Astellas Pharma Inc.
• 31.5. Ipsen SA
• 31.6. Exelixis Inc.
• 31.7. BeiGene Ltd.
• 31.8. Bavarian Nordic A/S
• 31.9. Telix Pharmaceuticals Limited
• 31.10. CRISPR Therapeutics AG
• 31.11. Beijing Scitech-Mq Pharmaceuticals Limited
• 31.12. HUTCHMED (China) Limited
• 31.13. Arcus Biosciences Inc.
• 31.14. NGM Biopharmaceuticals Inc.
• 31.15. Mirati Therapeutics Inc.

32. Global Advanced Renal Cell Carcinoma Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Advanced Renal Cell Carcinoma Treatment Market

34. Recent Developments In The Advanced Renal Cell Carcinoma Treatment Market

35. Advanced Renal Cell Carcinoma Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Advanced Renal Cell Carcinoma Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Advanced Renal Cell Carcinoma Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Advanced Renal Cell Carcinoma Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료